Other research analysts have also recently issued reports about the stock. Stephens began coverage on shares of Establishment Labs in a research report on Thursday, June 6th. They set an overweight rating and a $37.00 price target for the company. Wells Fargo & Co set a $29.00 price target on shares of Establishment Labs and gave the company a buy rating in a research report on Friday, July 12th. Finally, BTIG Research reissued a buy rating and set a $40.00 price target on shares of Establishment Labs in a research report on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $35.20.
NASDAQ ESTA traded down $0.33 during trading hours on Monday, reaching $25.04. 447 shares of the company’s stock traded hands, compared to its average volume of 55,534. Establishment Labs has a 52-week low of $20.05 and a 52-week high of $30.70. The company has a market cap of $515.33 million and a price-to-earnings ratio of -22.23. The business’s 50-day simple moving average is $22.60. The company has a current ratio of 5.54, a quick ratio of 4.10 and a debt-to-equity ratio of 0.38.
In other news, major shareholder Jw Asset Management, Llc acquired 2,500 shares of Establishment Labs stock in a transaction on Monday, July 29th. The stock was acquired at an average cost of $25.58 per share, for a total transaction of $63,950.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 2.64% of the stock is currently owned by company insiders.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.
Featured Article: Earnings Per Share
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.